Literature DB >> 15698606

CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.

Yong-Fang Hu1, Jun He, Guo-Lin Chen, Dan Wang, Zhong-Qi Liu, Che Zhang, Li-Fang Duan, Hong-Hao Zhou.   

Abstract

BACKGROUND: Human cytochrome P450 3A evolved to catalyze the metabolism of numerous common therapy drugs and endogenous molecules. Members of the CYP3A are the majority expressed in human liver and intestine, and there are marked interindividual differences in their protein expression and activity. The activity of CYP3A enzyme in Chinese is highly variable, exceeding 14-fold, and contributes greatly to variation in oral bioavailability and systemic clearance of CYP3A substrates. The genetic factors play an important role in the interindividual variability in CYP3A activity. Detection of CYP3A5 and CYP3A4 variant alleles and knowledge about their allelic frequency in specific ethnic groups are important to lead to individualized drug dosing and improved therapeutics.
METHODS: We determined the allelic frequency of the CYP3A5*3 and CYP3A4*18 in a group of 302 Chinese subjects by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assays.
RESULTS: In the group of 302 unrelated individuals, the frequency of the CYP3A5*3 and CYP3A4*18 variant allele in Chinese population were 0.778 (95% CI: 0.754, 0.802) and 0.01 (95% CI: 0, 0.02), respectively.
CONCLUSIONS: We developed a simple assay for the detection of the CYP3A4*18 allele and showed that in a Chinese population, CYP3A4*18 and CYP3A5*3 allelic frequencies are similar to that reported previously in Chinese resident in Taiwan. The frequency of the CYP3A5*3 allele in Chinese population is similar to the Japanese but lower than Caucasians. Meanwhile, our findings suggest that an approximate 62% of the Chinese population carrying CYP3A5*3/*3 genotype may appear not to express CYP3A5 protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15698606     DOI: 10.1016/j.cccn.2004.11.005

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  18 in total

1.  Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray.

Authors:  Yuanyuan Dong; Huasheng Xiao; Qi Wang; Chunxiu Zhang; Xiuming Liu; Na Yao; Haihui Sheng; Haiyan Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.

Authors:  Ya-Huei Liou; Chien-Ting Lin; Ying-Jye Wu; Lawrence Shih-Hsin Wu
Journal:  J Hum Genet       Date:  2006-08-19       Impact factor: 3.172

3.  Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.

Authors:  Hye-In Lee; Ji-Young Byeon; Young-Hoon Kim; Choong-Min Lee; Chang-Ik Choi; Choon-Gon Jang; Jung-Woo Bae; Yun Jeong Lee; Seok-Yong Lee
Journal:  Eur J Clin Pharmacol       Date:  2018-07-24       Impact factor: 2.953

4.  Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.

Authors:  Fabiana B Kohlrausch; Ángel Carracedo; Mara H Hutz
Journal:  Mol Biol Rep       Date:  2014-01-18       Impact factor: 2.316

5.  Genetic analysis of drug metabolizing phase-I enzymes CYP3A4 in Tibetan populations.

Authors:  Lijun Liu; Yu Chang; Shuli Du; Xugang Shi; Hua Yang; Longli Kang; Tianbo Jin; Dongya Yuan; Yongjun He
Journal:  J Genet       Date:  2017-06       Impact factor: 1.166

6.  The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.

Authors:  P Stratta; M Quaglia; T Cena; R Antoniotti; R Fenoglio; A Menegotto; D Ferrante; A Genazzani; S Terrazzino; C Magnani
Journal:  Eur J Clin Pharmacol       Date:  2011-11-20       Impact factor: 2.953

7.  Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.

Authors:  Nelson L S Tang; Chen Di Liao; Xingyan Wang; Frankie K F Mo; Vicky T C Chan; Rita Ng; Elizabeth Pang; Joyce J S Suen; Jean Woo; Winnie Yeo
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-10       Impact factor: 4.553

8.  Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.

Authors:  Sabrina Angelini; Simona Soverini; Gloria Ravegnini; Matt Barnett; Eleonora Turrini; Mark Thornquist; Fabrizio Pane; Timothy P Hughes; Deborah L White; Jerald Radich; Dong Wook Kim; Giuseppe Saglio; Daniela Cilloni; Ilaria Iacobucci; Giovanni Perini; Richard Woodman; Giorgio Cantelli-Forti; Michele Baccarani; Patrizia Hrelia; Giovanni Martinelli
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

9.  Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients.

Authors:  Paraskevi F Katsakiori; Eirini P Papapetrou; Dimitrios S Goumenos; George C Nikiforidis; Christodoulos S Flordellis
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

10.  Single nucleotide polymorphism of CYP3A4 intron 2 and its influence on CYP3A4 mRNA expression and liver enzymatic activity in human liver.

Authors:  Min Huang; Han-Ming Wang; Yu Guo; Jie Ping; Man Chen; Dan Xu; Hui Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.